Statement of Principles concerning thromboangiitis obliterans (Balance of Probabilities) (No. 29 of 2017)

The Statement is compact and conceptually narrow. Its principal legal concepts and how the instrument uses them are these.

• Statement of Principles and statutory role: The instrument is a Statement of Principles made under s 196B(3) VEA (s 3). The Statement is intended to set the RMA's view, based on the available medical‑scientific evidence, about which factors are sufficient, on the balance of probabilities, to connect a specified disease to relevant service (s 8). The instrument therefore functions as an evidentiary standard used in statutory decision‑making under the VEA and MRCA (s 5).

• Disease definition: Thromboangiitis obliterans is defined in technical clinical terms in s 7(2). The instrument notes the common name Buerger's disease and acknowledges the ICD‑10‑AM code I73.1 but states that the legal meaning for this Statement is the definition in s 7(2) (s 7(2)-(4)). This places emphasis on the statutory textual definition rather than reliance on coding alone.

• Inclusion of death: The Statement expressly includes "death from thromboangiitis obliterans", defined to include death from a terminal event or condition that was contributed to by the person's thromboangiitis obliterans (s 7(5) and Schedule 1 definition of "terminal event"). That is, the causal chain may be through contribution to a terminal episode such as pneumonia or cardiac arrest, as the Schedule expressly lists examples (Schedule 1).

• Factors for connection: The decisive legal mechanism is the list in s 9 of factors that must be shown before, on balance, the disease can be said to be connected to relevant service. The list is conjunctive with respect to the ultimate requirement that at least one factor must be present; it is disjunctive across the three alternatives. Two factors are temporal and quantifiable smoking thresholds (s 9(1)-(2)), and the third is a health‑services access factor (s 9(3)).

• Pack‑year methodology: The Schedule defines the "pack‑year" calculation in detail, converting one pack‑year to 20 tailor‑made cigarettes per day for a year (7,300 cigarettes), approximating one tailor‑made cigarette as one gram of tobacco and translating pack‑years into a weight measure (7.3 kilograms of smoking tobacco per pack‑year). The Schedule extends the pack‑year notion to pipe tobacco and cigars, treated as equivalent by weight when smoked alone or in combination (Schedule 1).

• Relevant service: The Schedule defines "relevant service" for this instrument as a limited set of VEA and MRCA service categories: eligible war service (other than operational service) under the VEA; defence service (other than hazardous service and British nuclear test defence service) under the VEA; and peacetime service under the MRCA (Schedule 1). The Statement therefore applies only to claims that fall within those service types.

• Interaction with other Statements: Section 11 provides that if a factor in s 9 refers to an injury or disease covered by another RMA Statement of Principles, then the factors in that other Statement apply as in force from time to time. This creates a cross‑reference network among Statements and lets other Statements’ criteria be invoked where relevant.

• Temporal limits and material contribution: Section 10 restricts how factors apply relative to the timing of disease onset. Importantly, ss 9(2) and 9(3) apply only where the person's disease was suffered or contracted before or during relevant service, and the claim is for material contribution to, or aggravation of, the condition (s 10(2)). Section 10(1) requires that any s 9 factor relied on be related to the person's relevant service.

These core concepts structure how decision makers will apply the RMA's medical view to claims: disease definition, quantification of smoking exposure, timing windows, an access‑to‑care alternative pathway, and cross‑reference to other Statements.

The Statement expressly governs the evidential criteria used in claims by veterans and members for whom the VEA or the MRCA applies. Section 5 states that the instrument applies to a claim to which s 120B of the VEA or s 339 of the MRCA applies. The Schedule defines the instrumental concept of "relevant service" for the Statement as (a) eligible war service (other than operational service) under the VEA; (b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or (c) peacetime service under the MRCA (Schedule 1). Putting those elements together identifies three principal actor groups affected.

• Claimants (veterans and members): Individuals who are claiming benefits under the VEA or MRCA and whose claims involve thromboangiitis obliterans or death from it, and whose service falls within the Schedule's "relevant service" categories, are directly affected. The Statement provides the permissible medical linkages that a claimant must show to establish that the disease is connected to relevant service on the balance of probabilities (ss 5, 8 and 9).

• Decision‑makers and administrators: Tribunal members, departmental decision makers, medical assessors and others who adjudicate claims under the VEA and MRCA will rely on this Statement as the RMA's view about medical causation for this disease. The instrument functions as an authoritative input to claim determinations (s 3 and s 8).

• Health practitioners and experts: Clinicians who provide reports for claims will need to address the factual elements the Statement identifies , dates of clinical onset and worsening, and measurements of tobacco consumption in pack‑years per the Schedule , because those elements are pivotal to establishing a connection under s 9.

• Legal advisers and representatives: Lawyers, advocates and advocates' agents preparing claims must marshal evidence mapped to the Statement's factors. Where a factor refers to another disease covered by another Statement, advisers will have to consult that other Statement as required by s 11.

• Records custodians and service agencies: Agencies that hold service records and medical records, and that are asked to produce evidence about service type or clinical management provided during service, will be involved in evidence production. The Statement's operation depends on establishing the relation of factors to "relevant service" (s 10).

Not affected by this instrument are persons whose service does not meet the Schedule's "relevant service" definitions, and claims outside the operation of s 120B VEA or s 339 MRCA. The Statement does not itself create liabilities or penalties against any party; it is a determinative, evidentiary instrument used in the statutory claims process (ss 3 and 5).

The Statement itself does not create duties, criminal offences or private rights outside the administrative process for claims; rather, it supplies the RMA's medical criteria that must be satisfied for a claim of connection to succeed under specified provisions of the VEA and MRCA (see s 5 and s 8). The practical legal "duties" and "rights" flow from how the Statement is applied to claims.

• Evidential duty on claimants: To establish the necessary connection, a claimant must show, on the balance of probabilities, that at least one of the factors in s 9 applied to them and that the factor is related to their relevant service (ss 9 and 10(1)). This creates a de facto evidential duty: if no factor from s 9 is established, the statutory test for connection described in s 8 cannot be satisfied by the RMA’s view.

• Temporal and causal qualification: For claims asserting material contribution or aggravation of pre‑existing disease, the claimant's duty is qualified. Factors in ss 9(2) and 9(3) apply only where the thromboangiitis obliterans was suffered or contracted before or during relevant service and did not arise out of relevant service, and the claim is that the service materially contributed to or aggravated the pre‑existing disease (s 10(2)). Practically this means claimants alleging material contribution or aggravation must establish the disease predates or is contemporaneous with service but did not originate in it, and then show the additional factor applies.

• Right to have RMA’s medical criteria applied: Claimants have the procedural right, under the VEA/MRCA claims process, to have the RMA's Statements of Principles applied to their claims. The Statement is determinative of the medical factors the Authority regards as sufficient on the balance of probabilities; decision‑makers must apply it where the statutory trigger sections (s 120B VEA or s 339 MRCA) are engaged (s 5 and s 8). The Statement gives claimants clarity about what medical findings will be considered sufficient.

• Right to rely on other Statements: Where a s 9 factor refers to an injury or disease covered by another Statement, the claimant can rely on the criteria in that other Statement, as that other Statement applies from time to time (s 11). This is a procedural right to cross‑invoke other RMA determinations.

• Duty on decision‑makers to treat the RMA’s view as relevant medical opinion: Section 8 records the RMA's view "on the sound medical‑scientific evidence available" that it is more probable than not that the disease can be related to relevant service. While the Statement itself does not bind courts or tribunals beyond the statutory process, decision‑makers administering s 120B VEA or s 339 MRCA must treat the factors as the RMA's authoritative medical view for those claim categories. The instrument therefore functions as a statutory benchmark in adjudication.

• Duty to interpret definitions consistently: The Schedule supplies precise definitions that must be used in applying the Statement. For example, calculation of pack‑years is defined numerically in the Schedule and must be applied when determining whether the smoking thresholds in s 9 are met.

• Procedural limitations: The Statement places no time limits on when a claim must be made; those are set by the VEA and MRCA. The Statement also does not provide the procedural steps to be followed, nor does it specify the species of evidence that must be produced to satisfy a factor; those remain matters for the VEA and MRCA decision processes and their evidentiary rules.

In short, the key practical obligations are evidentiary: claimants must establish at least one s 9 factor and that it is related to relevant service (s 10(1)); material contribution/aggravation claims are limited by s 10(2); and where other Statements are implicated, their criteria apply per s 11.

The Statement contains no penalties, offences, or enforcement mechanisms within its text. It is an authoritative medical criteria instrument for use in claims processes under the VEA and MRCA rather than a regulatory offence‑creating provision. The instrument's operative features concern definitions and factors for causation; enforcement and administrative consequences arise only through the application of those factors by decision‑makers in the VEA and MRCA frameworks.

Concretely:

• No statutory sanctions in the Statement: There are no sections in the Statement that create criminal liability, civil penalties, administrative fines, or compliance orders. It does not direct enforcement action against providers, claimants, or service agencies (the text is limited to definitions, factors, and cross‑references; see all of ss 1-11 and the Schedule).

• Administrative effect through adjudication: The functional "enforcement" effect is that decision‑makers assessing claims under section 120B of the VEA or s 339 of the MRCA will accept or reject a claim of service connection based on whether the Statement's factors are established. The practical consequence for claimants is grant or denial of benefits under those Acts; the Statement itself does not set out the benefit consequences , those are governed by the VEA and MRCA. The Statement does not describe the decision‑making process, appeal rights, or further remedies; those remain in the underlying statutes.

• Discretion and interpretative enforcement risk: Because the Statement leaves key concepts open to interpretation , for example, "inability to obtain appropriate clinical management" (s 9(3)) , the RMA’s medical criteria will be applied by administrative decision‑makers who must interpret and evaluate evidence. Any enforcement in practice is therefore through case‑by‑case assessment, which introduces uncertainty and discretion in outcomes. The Statement does not set objective procedural steps for adjudicators beyond specifying the factors themselves.

• Interaction with other laws for enforcement: Where a s 9 factor refers to an injury or disease with its own Statement, s 11 requires the other Statement's factors be applied "as in force from time to time." That creates potential dynamic enforcement effects: changes to other Statements can affect how a s 9 factor is treated in subsequent decisions.

• Appeals and legal enforcement outside the instrument: The Statement does not specify appeal routes. For claimants dissatisfied with administrative determinations under the VEA or MRCA, statutory appeal mechanisms in those Acts would govern any legal challenge. The Statement will be part of the evidentiary matrix in those appeals but does not itself create an enforcement or appeal regime.

In sum, enforcement is indirect: the Statement shapes entitlement and denial outcomes under the VEA and MRCA but contains no standalone penalties or enforcement provisions.

The Statement is explicitly designed to operate within and in support of the VEA and MRCA claims processes. The text itself provides the primary pointers to statutory interaction and cross‑references.

• Statutory authority and application: The Statement is made under subsection 196B(3) of the VEA (s 3). Section 5 says the instrument applies to claims to which s 120B of the VEA or s 339 of the MRCA applies. The instrument therefore functions as an RMA determination for specified claim categories under both the VEA and MRCA. The Statement must be read and applied as an input to decisions under those sections of the primary statutes.

• Relevant service definitions are statutory cross‑references: The Schedule defines "relevant service" by reference to categories contained in the VEA and MRCA, namely eligible war service, defence service (each qualified by exclusions), and peacetime service under the MRCA (Schedule 1). The Statement therefore imports, for application, the substantive meaning of those service categories as provided in the primary Acts. The Statement does not recapitulate the full definitions or thresholds that determine eligibility; those remain in the VEA and MRCA.

• Cross‑Statement application: Section 11 creates an explicit interaction mechanism for overlapping medical conditions. If a factor in s 9 refers to an injury or disease that is covered by another RMA Statement under s 196B(3), then the criterion in that other Statement applies "in accordance with the terms of that Statement as in force from time to time" (s 11). This makes Statements of Principles modular and interdependent; changes to another Statement can alter how a factor in this Statement is treated.

• ICD‑10‑AM acknowledgment: Section 7(3) and (4) acknowledge that thromboangiitis obliterans attracts ICD‑10‑AM code I73.1, and defines that references to ICD‑10‑AM codes are to the Ninth Edition, effective 1 July 2015. That aligns the Statement with recognised disease coding systems for administrative and statistical purposes, but the instrument makes clear that the operational legal meaning is the textual definition in s 7(2).

• Claim processing under VEA/MRCA: The Statement does not specify how evidence is to be tendered, how the decision‑making process operates or what remedies or benefits attach to a successful claim. Those procedural and entitlement consequences are governed by the VEA and MRCA. The Statement therefore acts as a technical evidentiary input to those primary statutes rather than displacing or varying them.

• Implied evidence standard interaction: The Statement frames causation in terms of the balance of probabilities and the RMA's view based on available medical‑scientific evidence (s 8). That interacts with evidentiary standards in the VEA and MRCA claims process, where decisions are typically made on administrative fact‑finding standards; how decision‑makers reconcile medical evidence, legal tests, and the RMA's Statement will depend on the interpretative frameworks of the principal Acts.

• No displacement of common law or other statutory duties: The Statement does not purport to displace general common law principles or any other statutory duties outside the VEA/MRCA claims context. It is narrowly scoped to claims under the cited sections (s 5).

Practically, claimants and advisers will need to consult the VEA and MRCA to understand the full legal consequences, time limits, evidentiary rules and appeal rights; the Statement supplies the RMA's medical criteria that those statutory processes must take into account.

The instrument contains limited historical material within itself. The Statement is identified as No. 29 of 2017 and dated 21 April 2017, with commencement on 22 May 2017 (ss 1-2). Section 4 records a single internal amendment history point: the Statement revokes the earlier Statement of Principles concerning thromboangiitis obliterans No. 8 of 2009, which had been made under subsection 196B(3) of the VEA.

Concretely:

• Creation and commencement: The text shows the Statement was made under the statutory authority in s 196B(3) VEA and was intended to become operative on 22 May 2017 (ss 2-3).

• Revocation of prior Statement: Section 4 expressly revokes Statement No. 8 of 2009. The instrument does not reproduce the text of the revoked instrument or set transitional provisions; it simply announces revocation. The practical effect is that, from 22 May 2017, the RMA’s No. 29 of 2017 Statement is the operative Statement for thromboangiitis obliterans within the RMA's portfolio, replacing the 2009 Statement.

• No other amendments recorded: The instrument does not record further amendment dates, variations, or subsequent revocations. There is no notation of amendments after commencement within the provided text.

• Dynamic interactions with other Statements: Section 11 contemplates that other Statements may be changed "from time to time" and that those changes will affect how a s 9 factor that refers to another disease is applied. That means the effective content of the causal matrix for a given claimant could change over time if other Statements are varied, but the instrument itself records only its own creation and the revocation of the 2009 Statement.

• No recorded transitional or savings clauses: The instrument does not include express transitional or savings provisions governing claims lodged before 22 May 2017, nor does it state whether decisions made under the 2009 Statement are subject to review in light of No. 29 of 2017. Any transitional legal consequences must be inferred from the broader statutory framework of the VEA and MRCA and administrative practice, but those are not contained in this text.

Users needing a complete amendment history should therefore consult RMA registers and the VEA/MRCA legislative amendment records outside this instrument. The Statement itself records only substitution of the earlier 2009 Statement and establishment of the 2017 Statement.

The provided instrument contains no litigation history. It does not reference, summarise or otherwise report on any judicial or tribunal decisions that have interpreted or considered the Statement of Principles concerning thromboangiitis obliterans (No. 29 of 2017) or the prior 2009 Statement. There are no case citations, no references to appeals, and no notes about how courts or tribunals have treated the Statement.

Implications of that absence in the text:

• No internal guide to contested interpretation: Because the instrument contains no reported decisions, it does not provide authoritative examples of how administrative decision‑makers or courts have applied its factors in contested cases. Practitioners must therefore rely on the instrument's textual content and consult external case law sources , for example decisions under the VEA, MRCA or on judicial review , to understand how the Statement has been interpreted in practice. The instrument itself does not supply that material.

• Potential for interpretive litigation: The Statement leaves certain terms and concepts undefined or open to fact‑sensitive inquiry, such as "inability to obtain appropriate clinical management" (s 9(3)), the assessment of when clinical onset or worsening occurred, and the application of pack‑year calculations in mixed‑product smokers. These are the kinds of issues that could give rise to litigation over interpretation or evidentiary sufficiency, but the instrument does not record whether litigation has actually occurred.

• Reliance on substantive statutes for remedies and appeals: Any litigation history relevant to this Statement would be generated in the context of appeals or judicial review of decisions under the VEA or MRCA that have had the Statement applied. The instrument does not address appeal channels, remedial orders, or precedent status; these matters must be explored in source materials external to the instrument.

• Practitioner action point: Because the Statement is silent on litigation history, advisers should search administrative tribunal and court databases for decisions that mention this Statement when advising clients about likely outcomes or appellate prospects. The Statement itself provides no guide to settled administrative practice or judicial treatment.

In short, the instrument does not record or summarise litigation; to obtain litigation history practitioners must consult external legal databases and administrative decisions.

The Statement appears straightforward but contains several technical traps and interpretive pressure points that practitioners and claimants should note when preparing or defending claims. Each of these is derived from the instrument's language and structure.

• Strict temporal windows for smoking factors: The smoking thresholds in s 9 are time‑limited. Factor 9(1) requires at least three pack‑years "within the three years before the clinical onset" of thromboangiitis obliterans. Factor 9(2) requires at least half a pack‑year "within the one year before the clinical worsening". If records place smoking exposure outside those windows, the smoking factors will not be satisfied. Accurate and documentable determinations of clinical onset and clinical worsening dates are therefore critical. The terms "clinical onset" and "clinical worsening" are not defined within the Statement; their identification will be a fact question.

• Pack‑year calculation specifics: The Schedule prescribes a particular pack‑year equivalence: one pack‑year equals 20 tailor‑made cigarettes per day for one year (7,300 cigarettes), and one tailor‑made cigarette approximates one gram of tobacco by weight. It converts to 7.3 kilograms of smoking tobacco per pack‑year (Schedule 1). Practitioners must apply this exact arithmetic and the Schedule's definitions of "tobacco products" when calculating exposure. If a claimant's tobacco consumption is described in imprecise terms, the conversion and rounding methods used may be determinative.

• Equivalence across product types: The Schedule treats cigarettes, pipe tobacco and cigars smoked alone or in any combination as "tobacco products" and uses weight equivalence to translate consumption into pack‑years. That requires converting non‑cigarette consumption into gram weight equivalents. If historical records do not specify amounts precisely, claimants may struggle to meet the numeric thresholds. The Statement leaves the practical method of establishing equivalence to adjudicators.

• "Inability to obtain appropriate clinical management" is unspecified: Factor 9(3) provides a non‑quantitative alternative to smoking exposure. However the Statement does not define what constitutes "appropriate clinical management" or what evidence suffices to show an "inability to obtain" it. This invites interpretive disagreement and places weight on contextual evidence about service‑era health care, access to specialists, treatment availability, and contemporaneous medical records. Establishing this factor will require careful evidence about the health system and treatment options that were actually available to the person during the relevant period.

• Limitation on aggravation/material contribution claims: Sections 9(2) and 9(3) operate only for "material contribution to, or aggravation of" thromboangiitis obliterans where the disease was suffered or contracted before or during (but did not arise out of) the relevant service (s 10(2)). This means that for claims that assert the disease first arose out of service, the smoking‑within‑one‑year and inability‑to‑obtain‑management factors are not available as aggravation pathways. Claimants and advisers must classify the claim correctly between "arose out of" and "material contribution/aggravation".

• Relationship to "relevant service": Section 10(1) requires the factor relied on to be "related to the relevant service rendered by the person." The Schedule defines "relevant service" in narrow terms and excludes, for example, operational service, hazardous service and British nuclear test defence service in certain definitions. Claims based on service that falls outside the Schedule's definitions will not be within the instrument’s scope.

• Cross‑Statement dependencies: Section 11 brings other Statements into play where a s 9 factor refers to a disease covered by another Statement. This can create layered dependency risk: the availability of a factor may depend on the terms of another Statement, and those terms can change "from time to time". Practitioners must check the current versions of implicated Statements.

• ICD‑10‑AM reference is nominal: Section 7(3) notes the ICD‑10‑AM coding but clarifies that the Statement’s meaning is the textual definition in s 7(2). Reliance on a diagnosis code alone without addressing the definition elements could leave gaps in adjudication.

• No procedural guidance on evidence standard: The Statement specifies the causation standard (balance of probabilities in s 8) but does not instruct how to operationalise proof. Administrative decision‑makers will still require appropriate evidence and may adopt differing approaches to weight and probative value. Claimants should not assume the numeric thresholds guarantee success without substantiating documentation.

• Revocation of prior Statement: The 2009 Statement is revoked (s 4). If prior claim decisions were made under the old Statement, the practical consequences (for ongoing appeals or re‑opened matters) depend on the broader VEA/MRCA law and administrative practice which are not set out here. Practitioners should check whether any transitional arrangements or precedential decisions are relevant.

Each of these "gotchas" flows directly from the text. They are points where evidential detail, precise chronology, and definitional clarity will determine outcomes.

The Statement requires proof that at least one of the factors in s 9 is met and that the factor is related to the person's relevant service (s 9; s 10(1)). Compliance for claimants, advisers and clinicians therefore focuses on assembling specific, chronologically anchored evidence and mapping it to the Statement's defined concepts. The steps below are practical measures, grounded in the instrument’s text, for meeting the Statement’s criteria.

1. Establish the relevant service category and link it to the claim

• Confirm the claimant’s service type falls within the Schedule’s definition of "relevant service" (eligible war service other than operational service, defence service other than the specified exclusions, or peacetime service under MRCA) (Schedule 1).
• Obtain service records showing dates and characterisation of service. The Statement requires that any s 9 factor relied upon be "related to the relevant service" (s 10(1)), so documentary proof of the service and its timing is necessary.

2. Document clinical onset and clinical worsening dates

• Identify and document the "clinical onset" date for thromboangiitis obliterans and any dates of "clinical worsening". These dates are central because the smoking thresholds are tied to time windows relative to onset and worsening (s 9(1)-(2)).
• Source contemporaneous medical records, specialist notes, imaging reports, surgical records (e.g., amputations), or diagnostic statements that can anchor clinical onset and worsening to dates.

3. Calculate pack‑years strictly using the Schedule’s method

• Use the Schedule’s calculation: one pack‑year equals 20 tailor‑made cigarettes per day for one year, which equals 7,300 cigarettes, and one tailor‑made cigarette approximates one gram of tobacco by weight; one pack‑year equates to 7.3 kilograms of smoking tobacco (Schedule 1).
• Convert all tobacco consumption into gram equivalents, including pipe tobacco and cigars, to determine the pack‑year total. Document the source of the consumption statements (medical notes, general practitioner histories, contemporaneous diaries, family statements).
• For s 9(1), show at least three pack‑years within the three years before clinical onset. For s 9(2), show at least 0.5 pack‑years within the year before clinical worsening.

4. Prepare evidence for the "inability to obtain appropriate clinical management" alternative

• If relying on s 9(3), assemble evidence demonstrating that the claimant was unable to obtain appropriate clinical management for thromboangiitis obliterans during the relevant period.
• Relevant evidence might include contemporaneous requests for care, referrals, correspondence showing refusal or lack of available services, service medical centre records, evidence of geographical or logistical barriers to specialty care during service, and clinical notes documenting foregone or delayed management.
• The Statement does not define "appropriate clinical management", so include clinical statements from treating specialists describing what management would have been appropriate and explaining why it was not available or obtained.

5. Address cross‑referenced Statements where relevant

• If any s 9 factor refers to an injury or disease that is covered by another Statement, obtain and apply that other Statement's current factors as required by s 11. Check the RMA's repository for the current version of any implicated Statements.

6. Provide clear medico‑legal or specialist reports

• Clinicians and medico‑legal experts should explicitly map their opinions to the Statement's elements: identify clinical onset and worsening dates; calculate and state pack‑years per the Schedule; opine on whether the disease, or its worsening, was contributed to by smoking in the specified time windows or by lack of appropriate management; and explain the relationship to the claimant’s relevant service.
• Since the Statement frames causation on the balance of probabilities (s 8), expert reports should state whether, on the balance of probabilities, the s 9 factor is met.

7. Anticipate the burden of proof and evidentiary gaps

• Where records are incomplete, develop corroborating evidence: sworn statements from family or colleagues about smoking habits, service facility capability at the time, or historical context for treatment availability. The Statement itself does not mandate specific evidence types; decision‑makers may weigh such evidence variably.
• Be prepared to address ambiguities in dates or consumption amounts, and to explain any assumptions used in pack‑year calculations.

8. Record and map all evidence to statutory language

• Produce a short mapping memorandum that links each evidentiary item to the precise statutory phrase in the Statement: e.g., "Clinical onset dated 1 March 2014 (GP note X). Smoking consumption 20 cigarettes per day from 1 Jan 2011 to 31 Dec 2013 = 3 pack‑years = meets s 9(1) within 3 years before clinical onset." This helps adjudicators apply the Statement’s numeric thresholds.

9. Check for excluded service types and transitional implications

• Confirm that the claimant’s service is not excluded by the Schedule's qualifications (for example, operational service is excluded in certain parts of relevant service). If service falls outside these categories, the Statement will not apply.
• If the claim arises near the time of the Statement's revocation of the 2009 instrument, consider whether any administrative policy or transitional practice applies; the Statement itself records the revocation but not transitional rules (s 4).

10. Prepare for cross‑examination on definitional choices

• Expect decision‑makers or opposing parties to contest onset dates, pack‑year conversions, the adequacy of evidence of inability to obtain care, and whether the factor is related to relevant service (s 10(1)). Ensure expert statements justify interpretations and provide clinical rationale.

These compliance steps are driven by the instrument’s text. They focus on acquiring precise, dated, and quantified evidence that maps directly to the Statement's three factors and on ensuring the service qualifies as "relevant service" as defined in the Schedule. Where the Statement is silent on procedure or evidence sufficiency, practitioners should follow the evidentiary rules and appeal avenues provided by the VEA and MRCA and anticipate the interpretive issues flagged above.